# Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY

> **NCT04789980** · — · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 799 (actual)

## Conditions studied

- Locally Advanced Pancreatic Cancer
- Metastatic Pancreatic Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04789980
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-29
- **Primary completion:** 2025-06-24
- **Final completion:** 2025-06-24
- **Target enrollment:** 799 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04789980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04789980, "Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04789980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*